SAVIMS

SAVIMS logo white
Menu

COVID-19

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Increasing Epidemiological Relevance of Vaccinated Individuals in COVID-19 Transmission

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccines, Viral illnesses

Reference: Kampf, G. (2021). The epidemiological relevance of the COVID-19-vaccinated population is increasing. The Lancet Regional Health – Europe, 11, 100272. https://doi.org/10.1016/j.lanepe.2021.100272 Summary: High COVID-19 vaccination rates were anticipated to diminish SARS-CoV-2 transmission; however, recent findings suggest the opposite. In the UK, secondary attack rates among household contacts exposed to fully vaccinated individuals were similar […]

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Understanding RRR and ARR in Vaccine Trials

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Other scientific evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine risk benefit analysis, Vaccines, Viral illnesses

Reference: Iriarte, I., & Phoenix, S. (2021). Understanding relative risk reduction (RRR) and absolute risk reduction (ARR) in vaccine trials. PANDA. https://www.pandata.org/understanding-relative-risk-reduction-and-absolute-risk-reduction-in-vaccine-trials/ Summary: The article discusses the critical distinctions between Relative Risk Reduction (RRR) and Absolute Risk Reduction (ARR) in the context of vaccine trials, particularly those for COVID-19. RRR compares the efficacy of one

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Detection of Graphene in COVID-19 Vaccines

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Campra, P. (2021). Detection of graphene in COVID-19 vaccines by micro-Raman spectroscopy. Technical Report. Almeria, Spain: Universidad de Almería. Summary: This technical report by Professor Pablo Campra investigates the presence of graphene in various COVID-19 vaccine samples using a technique called micro-Raman spectroscopy. The study screened seven vials from four different vaccine brands, identifying

COVID-19, Reference Library

More Harm Than Good

| | COVID-19, Reference Library

Summary The Pfizer COVID 19 inoculations have come under scrutiny for potential harm and failure to adhere to established safety protocols. Concerns have been raised regarding biased reporting by pharmaceutical companies, including Pfizer. The trials conducted by Pfizer have been criticised for their design, with flaws in the comparison groups and endpoints. The immunobridging trials

COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Efficacy and Safety of BNT162b2 mRNA Covid-19 Vaccine at 6 Months

| | COVID-19, Covid-19 vaccines, Epidemiological surveillance, Peer-reviewed evidence, Resource Type, Statistical evidence, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. The New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The BNT162b2 mRNA vaccine demonstrates high efficacy and safety against Covid-19,

COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Safety and Efficacy of BNT162b2 mRNA Covid-19 Vaccine through 6 Months

| | COVID-19, Covid-19 vaccines, Peer-reviewed evidence, Resource Type, Vaccine effectiveness, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Thomas, S. J., Moreira, E. D. Jr., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., … & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385(19), 1761-1773. https://doi.org/10.1056/NEJMoa2110345 Summary: The article investigates the safety and efficacy of the BNT162b2 mRNA Covid-19

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Updated COVID-19 Adverse Events Following Immunisation

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: CEPI. (2022, October). COVID-19 AESI including status of associated Brighton case definitions. Retrieved from [insert URL here] Summary: The document presents an updated list of Adverse Events Following Immunisation (AESI) related to COVID-19, alongside their Brighton case definitions. It categorises various conditions such as acute respiratory distress syndrome, myocarditis, and thrombosis, indicating their publication

COVID-19, Reference Library

Dr Peter McCullough Affidavit – Interdict Application Children

| | COVID-19, Reference Library

Summary The document outlines Dr Peter McCullough’s serious concerns about the safety of COVID 19 vaccines, particularly in children. Dr McCullough, an expert in cardiology and internal medicine with a wealth of experience in medical research and publications, argues that the vaccines may carry risks and questions the accuracy of the data used for their

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19 Associated Events of Special Interest: A Comprehensive Overview

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: CEPI. (2021). COVID-19 associated events of special interest including status of associated Brighton case definitions. Retrieved from https://docs.google.com/spreadsheets/d/1QgF35nYcsaFN3DZTOtV_lP0TYqQzsDMUQBAd5M9brrM/edit#gid=1666959512 Summary: This document provides an overview of COVID-19 associated events of special interest (AESI) alongside their Brighton case definitions as of October 2021. It categorises AESIs into three groups: those seen with COVID-19 disease, those with

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Concerns Over COVID-19 Vaccination for Children Aged 5-11

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Kennedy, R. F., & Nass, M. (2021). Concerns over COVID-19 vaccination for children aged 5-11. Retrieved from Children’s Health Defense. Summary: In a letter to the FDA and VRBPAC members, Children’s Health Defense (CHD) expressed strong opposition to the potential Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children aged 5-11. The

Scroll to Top